DraftUnitedHealthcarePolicy CS198.I

Chemotherapy Observation or Inpatient Hospitalization

Defines medical necessity criteria for observation stays or inpatient hospitalization for adult cancer chemotherapy administration and monitoring; applies to UnitedHealthcare coverage decisions (excludes individuals under 18).

Policy Summary

PayerUnitedHealthcare

PolicyChemotherapy Observation or Inpatient Hospitalization

Policy CodePolicy CS198.I

Change TypeNo material change

Effective DateApr 1, 2025

Next Review Date

Key ActionDocument clinical rationale and monitoring plan for ambulatory multi-day infusional chemotherapy and follow plan-specific prior authorization and clinical review procedures for inpatient extensions.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

18+Age restriction (policy does not apply to individuals under 18)

MultipleRegimens often requiring inpatient monitoring

Examples listedObservation vs inpatient conditions

InterQualInterQual references for case review

18Sample size in cited EPOCH series

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

ASCO-ONS 2024Standards referenced

Coverage Criteria — Observation vs Inpatient for Chemotherapy

Inpatient medical necessity

Inpatient stay is medically necessary for chemotherapy when ANY of the following apply (examples provided in policy):

Regimens requiring inpatient monitoring or complex administration over multiple days (examples include continuous infusions or multi-day coordination >96 hours such as EPOCH/DA-EPOCH/R-EPOCH, ESHAP/R-ESHAP, Hyper-CVAD, high-dose methotrexate with leucovorin rescue, interleukin-2 infusions, high-dose ifosfamide >1 g/m2/day)

Specific factors prompting inpatient stay include need for continuous cardiac monitoring, close serum electrolyte/creatinine/methotrexate level monitoring, bladder irrigation, urine alkalinization, vasopressor support, or proximity to ICU.

Clinical conditions requiring inpatient stay: Acute leukemia; intra-arterial infusion of chemotherapy; prophylaxis of tumor lysis syndrome in cases of high-grade lymphoma with large masses

Conditions not listed will be reviewed case-by-case using InterQual LOC tools for medical necessity determination.

Observation indications

Observation stay may be appropriate for the following chemotherapy-related conditions:

Observation conditions: Known hypersensitivity reaction from prior infusion; congestive heart failure or chronic renal failure requiring high-volume fluid infusions; transcatheter arterial chemoembolization (TACE) or intra-arterial chemotherapy infusion

These are examples; other situations may be considered for observation and will be reviewed case-by-case.

This Medical Policy does not apply to the states listed below; refer to the state-specific policy or guideline for coverage determinations in those jurisdictions: Idaho, Indiana, Kansas, Kentucky, Nebraska, New Jersey, New Mexico, North Carolina, Ohio, Pennsylvania, and Tennessee.

The policy history includes administrative revisions that removed or modified state-specific application language. For example, the template update on 04/01/2026 removed language pertaining to Louisiana; earlier updates added or removed other states (including Nebraska, North Carolina, Mississippi, Idaho, and Kansas). Refer to the state-specific policy versions for the current applicability in any given state.

Most cancer chemotherapies can be administered safely and effectively in a physician’s office or via home health services. An inpatient stay is not required for routine chemotherapy unless the regimen or the patient’s clinical condition necessitates more intensive monitoring or complex multi-day administration that cannot be managed in ambulatory settings.

Regimens Commonly Requiring Observation or Inpatient Monitoring

Regimen	Typical drugs / schedule	Indication	Factors contributing to need for inpatient stay	Coverage status
EPOCH / DA-EPOCH / R-EPOCH
Etoposide 50 mg/m2/day continuous infusion days 1–4; Prednisone; Vincristine IV days 1–4; Doxorubicin 10 mg/m2/day continuous infusion days 1–4; Cyclophosphamide 750 mg/m2 IV day 5; with or without Rituximab
Lymphoma
Coordination of multiple infusions or multiple drugs over >96 hours; need for close monitoring during continuous multi‑day infusion
Covered with criteria

Regimen	Typical drugs / schedule	Indication	Factors contributing to need for inpatient stay	Coverage status
ESHAP / R-ESHAP
Etoposide 40 mg/m2/day continuous infusion days 1–4; Methylprednisolone; Cisplatin 25 mg/m2 continuous infusion days 1–4; Cytarabine high‑dose (e.g., 2 g/m2)
Lymphoma
Coordination of multiple infusions or multiple drugs over >96 hours; monitor for CNS toxicity with cytarabine
Covered with criteria

Regimen	Typical drugs / schedule	Indication	Factors contributing to need for inpatient stay	Coverage status
Interleukin‑2 infusion (IL‑2)
Interleukin‑2 600,000 IU/kg IV every 8 hours for up to 14 doses over 5 days
Melanoma; Renal cell cancer
Requires continuous cardiac monitoring; close monitoring of serum electrolytes, creatinine, bilirubin, urine output; potential need for vasopressor support and proximity to ICU
Covered with criteria

Model / example	Outpatient protocol summary	Initial inpatient requirement	Monitoring and follow‑up	Coverage status
Ambulatory EPOCH infusion model
Day 1 inpatient rituximab at outpatient infusion center then outpatient continuous combination infusion (etoposide, vincristine, doxorubicin) replaced every 24 hours on days 2–4; cyclophosphamide given after 96 hours
Initial cycle may be given inpatient prior to outpatient continuous infusion
Outpatient infusion pump with daily/24‑hour drug replacement; twice‑weekly laboratory monitoring and clinic follow‑up; patient education per institutional protocol
Informational (covered with documentation when criteria met)

Provider Responsibilities, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization and Benefit Plan Verification

Prior authorization may be required. Verify the member's federal, state, and contractual benefit plan terms before using this policy to determine coverage and authorization requirements.

Confirm benefit plan terms and any state/federal mandates prior to submitting authorization requests
Coverage determinations are governed by the member's plan; in case of conflict, federal/state/contractual requirements prevail

Documentation Required

Clinical Review and InterQual Reference

Requests for inpatient admission extensions or stays that exceed recommended durations require clinical review. UnitedHealthcare may reference InterQual® level-of-care (LOC) criteria (e.g., Acute Adult Hematology/Oncology: Complications, Disease Progression, or Treatments) when evaluating medical necessity.

Requests for inpatient extension beyond recommended days require contemporaneous clinical documentation and will undergo clinical review

Background and Definitions

Chemotherapy may be given in multiple settings — home, office, outpatient clinic, observation unit, or inpatient hospital — depending on the specific regimen, route of administration, and individual patient factors. Regimens that involve continuous multi-day infusions, require close laboratory or cardiac monitoring, or carry risks necessitating immediate access to higher-level support are examples of situations that may require inpatient care.

TACE — definition of Transcatheter Arterial Chemoembolization

DefinitionTranscatheter Arterial Chemoembolization (TACE) — a procedure in which the blood supply to a tumor is blocked after anticancer drugs are given in blood vessels near the tumor (NCI, 2022).

Ambulatory EPOCH — outpatient/ambulatory administration model

Model descriptionAmbulatory EPOCH — outpatient/ambulatory administration model in which an initial cycle may be given inpatient followed by outpatient continuous infusion (etoposide, vincristine, doxorubicin combined solution replaced every 24 hours on days 2–4) with a clinic-administered cyclophosphamide after ~96 hours and planned twice-weekly laboratory monitoring.

Initial inpatient care

Policy Revision History

2026-04-01administrativeLatest

Template update with removal of content/language pertaining to the state of Louisiana.

2025-11-01administrative

Policy updated to indicate the Medical Policy does not apply to Nebraska and North Carolina (state-specific policy versions referenced).

2025-07-01administrative

Policy Summary

PayerUnitedHealthcare

PolicyChemotherapy Observation or Inpatient Hospitalization

Policy CodePolicy CS198.I

Change TypeNo material change

Effective DateApr 1, 2025

Next Review Date

SourceLink

On This Page

InterQual LOC may be used as an objective reference for level-of-care decisions

Documentation Required

Required Written Protocol and Extension Review

Providers administering chemotherapy that requires inpatient monitoring or complex multi-day administration must follow a written protocol and have a process for review of any inpatient stay extensions.

Maintain a written protocol describing monitoring, administration, and safety procedures for inpatient chemotherapy regimens
Have a documented process for requesting and clinically justifying extensions of inpatient stays

Note

Follow ASCO-ONS Sequencing and Monitoring

When transitioning care settings (inpatient to outpatient/home or ambulatory infusion), follow ASCO-ONS standards for sequencing, monitoring, and safety, including patient education, consent, ordering/preparation/administration processes, and monitoring for adherence, toxicity, and complications.

Adhere to ASCO-ONS 2024 guidance on creating a safe environment, patient consent/education, and monitoring during and after antineoplastic therapy
Document the monitoring plan and follow-up schedule when using ambulatory or home infusion models (e.g., frequency of labs, toxicity surveillance)

Denial Risk

Case-by-Case Review and Denial Risk

Requests for care outside the listed indications or conditions (including observation vs inpatient decisions) will be reviewed on a case-by-case basis and may be denied if clinical justification is insufficient.

Provide thorough clinical justification and supporting documentation for requests outside stated indications to avoid denial risk
Be prepared to supply InterQual-relevant documentation if requested

Initial cycle administered in the hospital before transition to outpatient infusion center for subsequent continuous infusions replaced daily.

Infusion logisticsCombination infusion (etoposide, vincristine, doxorubicin) replaced every 24 hours during days 2–4; cyclophosphamide given after 96 hours at clinic.

MonitoringFollow-up blood tests twice per week during outpatient infusion period.

Patient-reported outcomesParticipants reported improved quality of life and a preference for home chemotherapy with no unexpected adverse safety effects in the cited case series.

ASCO-ONS 2024 guidance — standards for antineoplastic therapy

ScopeASCO-ONS 2024 guidance — updated multidisciplinary standards covering ordering, preparing, dispensing, administering, and monitoring antineoplastic therapies across facility and home settings.

Terminology update2024 guidance shifts terminology from 'chemotherapy' to 'antineoplastic therapy' to encompass newer modalities (oral targeted agents, immunotherapies, bispecifics, CAR T-cell therapies).

Key sectionsGuideline sections include: creating a safe environment; patient consent and education; ordering/preparing/dispensing/administering oral and parenteral therapies in facilities or home; and monitoring during and after therapy for adherence, toxicity, and complications.

Responsibility emphasisEmphasizes the respective responsibilities of all parties involved in antineoplastic therapy delivery to minimize errors and enhance safety and efficiency.

Template update with removal of content/language pertaining to the state of Mississippi.

2025-06-01administrative

Policy updated to indicate the Medical Policy does not apply to Idaho and Kansas (state-specific policy versions referenced).

2025-04-01administrative

Supporting Information updated: Clinical Evidence and References refreshed; previous policy version CS198.H archived.